Statins may help prolong survival in NSCLC resection

Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins.

Researchers from Northwestern University Feinberg School of Medicine, Chicago, and Penn State Hershey Cancer Institute followed 803 patients who underwent resection for , of which 315 were using statins.

Results showed that statin use was associated with a significantly lower local recurrence rate and significantly higher overall survival compared with non-statin users.

Researchers conclude that prospective studies are needed to assess the role of statin therapy as an adjunct to current multimodality regimens.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Study finds no link between statins and cancer risk

Jul 25, 2011

(Medical Xpress) -- A new study published in the Journal of the American College of Cardiology reports that, contrary to previous studies, the use of cholesterol reducing statin drugs does not increase the risk of patien ...

Recommended for you

Endogenous hormones improve breast cancer risk models

1 hour ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

2 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments